Endpoint
Endpoint Health develops precision therapies for immune-mediated diseases using its proprietary AI platform and combining companion diagnostics with therapeutics.
Secondary Market Price
How Endpoint Measures Up
To help you manage your Endpoint equity, Prospect has run the company through our machine learning model.
Prospect Rating
--
This rating reflects our belief in this company's potential to grow to that many times its current value in 4 years. For an employee with stock, this rating suggests a potential return on equity, but it also comes with some risk.
Exit Risk
--
Our rating is a reflection of the likelihood of this company achieving a liquidity event for its employees based on the quality of investors, funding stage, founders, and more.
Funding Stage
Series A
A company’s funding stage reflects how established it is, how quickly it is scaling, and the average impact an employee may have when joining.
Secondary Market Price Chart
Create a free account to unlock real-time secondary market prices and future projections of Endpoint's value.
Sign up to Unlock the Latest DataData will be available soon.
Sign up to receive notifications when it is available.
Prospect Projected Future Endpoint Prices
Prospect’s machine learning model has been trained on the same data top-tier investors use to project the likely range of outcomes for Endpoint's equity. Create a free account to view 10th-90th percentile projections over 2, 4, and 6 years.
Powerful tools to earn more from your equity
Company Description
Endpoint Health is a biotechnology company that develops precision immunology therapies for immune-mediated illnesses. The company focuses on conditions such as sepsis, acute respiratory distress syndrome (ARDS), and rheumatoid arthritis, leveraging a proprietary artificial intelligence platform that combines companion diagnostics with therapeutics. Founded in 2018 by co-founders Jason Springs, Diego Rey, and Leonardo Teixeira, the company operates in the biotechnology research sector with a headquarters in Palo Alto, California.
While the company has not detailed specific future plans or products, it secured a Series A funding round of $52 million in July 2022. This financing supports the company's continued efforts to advance its platform and develop its therapeutic solutions. The focus remains on addressing unmet needs in both chronic and acute immune-mediated diseases by tailoring treatments to a patient's specific biology.
- The Vanguard Group, Inc.
- BlackRock, Inc.
- State Street Corporation
- FMR LLC
- JPMorgan Chase & Co.
- Invesco Ltd.
- Geode Capital Management, LLC
- Dimensional Fund Advisors LP
- Founder, Scott Martino
Peer Group Comparison
Vs Peer Group of >$4B Startups
Frequently Asked Questions
Joining Anduril as an employee is another way to acquire equity, typically through stock options included in compensation packages.
Is Endpoint worth joining?
Deciding whether to join a company like Endpoint depends on your personal career goals and financial situation. Tools like Prospect can help you evaluate the potential future value of your equity compensation, which is a critical part of the decision-making process.
What should I do with my Endpoint stock?
Managing private company stock involves complex decisions about when to exercise options and how to plan for taxes. Using a platform like Prospect can help you build a customized strategy based on your financial goals and the company's outlook.
Can you sell Endpoint stock?
As a private company, selling Endpoint stock is typically restricted and only possible during specific events like company-approved tender offers or on secondary markets. Prospect offers tools to help you navigate these opportunities and decide how much equity to sell for the best tax outcome.
How can I find the value of my Endpoint stock?
The value of private stock like Endpoint's isn't publicly listed and is determined by internal 409A valuations and recent funding rounds. To get a better forecast, Prospect uses predictive models trained on data from top VCs to project the future value of your shares.
What is Endpoint's equity worth?
The total worth of your Endpoint equity depends on the company's future performance, potential exit scenarios, and your specific grant details. Platforms like Prospect can help you model different scenarios to understand the potential range of outcomes for your holdings.
What is Endpoint's stock ticker symbol?
Endpoint does not have a stock ticker symbol because it is a private company and its shares are not traded on a public stock exchange. Ticker symbols are assigned to companies only when they undergo an Initial Public Offering (IPO).
Can I buy or sell Endpoint stock?
As Endpoint is a private company, its stock is not available for purchase by the general public on stock markets, and selling is typically limited to specific liquidity events like tender offers. Employees can acquire stock by exercising their options, a process that platforms like Prospect can help optimize for tax purposes.
What is the criteria to buy or invest in Endpoint stock?
Investing in a private company like Endpoint is generally restricted to accredited investors, venture capital firms, and employees who are exercising their stock options. The general public cannot typically buy shares until the company goes public through an IPO.
